Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 656
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Urologiia ; (2): 13-19, 2023 May.
Article in Russian | MEDLINE | ID: mdl-37401699

ABSTRACT

BACKGROUND: Bladder catheterization is a common medical manipulation that is associated with the risk of complications, including catheter-associated urinary tract infection (CAUTI), which accounts for 80% of all nosocomial infections of the urological profile. AIM: To evaluate the combined use of the biologically active additive Uronext and ceftriaxone in the prevention of the development of CAUTI in the early postoperative period in 120 patients aged 20-80 years with a Foley indwelling catheter. MATERIALS AND METHODS: The patients were divided into 2 groups: in group I (n=60), D-mannose with cranberry extract and vitamin D3 as part of Uronext dietary supplement was administered orally in the form of sachets 48 hours before surgery and after surgery until urethral catheter was placed, as well as intravenous ceftriaxone 1000 mg 2 hours before surgery and in the postoperative period within 7 days. In group II (n=60), ceftriaxone monotherapy was prescribed in a similar way. RESULTS: According to the results of bacteriological examination of the removed urinary catheter on 3-7 days in Uronext group, bacterial growth was absent in 40 patients (66.67%, p<0.05), versus 23 cases (38.33%) in the control group. CONCLUSIONS: The data obtained confirm the efficiency of the use of the biologically active additive Uronext in combination with an antibacterial drug, which allows to recommend this scheme in patients with an indwelling urinary catheter for the prevention of the development of CAUTI.


Subject(s)
Catheter-Related Infections , Ceftriaxone , Cross Infection , Urinary Tract Infections , Humans , Catheter-Related Infections/prevention & control , Catheters, Indwelling/adverse effects , Catheters, Indwelling/microbiology , Ceftriaxone/therapeutic use , Cross Infection/microbiology , Cross Infection/prevention & control , Urinary Catheterization/adverse effects , Urinary Catheters/adverse effects , Urinary Tract Infections/prevention & control , Urinary Tract Infections/microbiology , Male , Adult , Middle Aged , Aged , Aged, 80 and over
2.
Arch Microbiol ; 205(4): 115, 2023 Mar 14.
Article in English | MEDLINE | ID: mdl-36917278

ABSTRACT

Infections by ESKAPE (Enterococcus sp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens cause major concern due to their multi-drug resistance (MDR). The ESKAPE pathogens are frequently linked to greater mortality, diseases, and economic burden in healthcare worldwide. Therefore, the use of plants as a natural source of antimicrobial agents provide a solution as they are easily available and safe to use. These natural drugs can also be enhanced by incorporating silver nanoparticles and combining them with existing antibiotics. By focussing the attention on the ESKAPE organisms, the MDR issue can be addressed much better.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Multiple, Bacterial , Gram-Negative Bacteria , Gram-Positive Bacteria , Plant Extracts , Drug Resistance, Multiple, Bacterial/genetics , Humans , Plants/chemistry , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Metal Nanoparticles/chemistry , Metal Nanoparticles/therapeutic use , Silver/chemistry , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Gram-Positive Bacteria/classification , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/genetics , Gram-Negative Bacteria/classification , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/genetics , Cross Infection/drug therapy , Cross Infection/microbiology
3.
Front Cell Infect Microbiol ; 12: 839257, 2022.
Article in English | MEDLINE | ID: mdl-35444955

ABSTRACT

Objectives: This is a comparative cohort study aiming to evaluate the mortality risk factors for patients with nosocomial meningitis (NM) induced by multidrug-resistant Enterobacteriaceae (MDRE) in China. The clinical features and therapies of patients and the resistance mechanisms of MDRE pathogens were also assessed. Methods: MDRE-NM patients from two neurosurgical centers in China from 2014 to 2019 were included in this study. Clinical features were extracted from the medical record databases of the two centers. The molecular mechanisms underlying the microbiological resistance mechanisms of each MDRE pathogen were determined, Kaplan-Meier survival analysis was conducted, and multivariable analyses were performed using a Cox proportional hazard model. Results: Ninety MDRE-NM patients were included in this study. Klebsiella pneumoniae accounted for the highest proportion of causative pathogens (46/90, 51.1%), and 40 causative pathogens (44.4%) were meropenem-resistant. blaKPC (27/40, 67.5%) was the predominant carbapenem resistance gene. Multivariate Cox analysis showed that external ventricular drainage (EVD) [hazard ratio (HR) = 2.524, 95% confidence interval (CI) = 1.101-5.787, p = 0.029] and a Glasgow Coma Scale (GCS) score ≤;8 (HR = 4.033, 95% CI = 1.526-10.645, p = 0.005) were mortality risk factors for patients with MDRE-NM. A total of 90.0%, 94.4%, and 97.8% of MDRE-NM patients received antibiotic prophylaxis (AP), antibiotic empirical therapy (AET), and antibiotic definitive therapy (ADT), respectively. Conclusions: NM caused by MDRE is an important sign of the failure of neurosurgery. MDRE possesses multiple drug resistance genotypes, and EVD and a GCS score ≤;8 are independent mortality risk factors for patients with MDRE-NM, which deserve the attention of microbiologists and neurosurgical clinicians.


Subject(s)
Cross Infection , Hemorrhagic Fever, Ebola , Meningitis , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , China/epidemiology , Cohort Studies , Cross Infection/drug therapy , Cross Infection/epidemiology , Cross Infection/microbiology , Drug Resistance, Bacterial , Drug Resistance, Multiple, Bacterial/genetics , Enterobacteriaceae/genetics , Humans , Longitudinal Studies , Microbial Sensitivity Tests
4.
S Afr Med J ; 112(1): 13520, 2022 02 02.
Article in English | MEDLINE | ID: mdl-35140001

ABSTRACT

BACKGROUND: Incorrect empirical antibiotic therapy is one of the factors that contribute to poor clinical outcomes and the development of antimicrobial resistance. Knowledge of the local infectious disease burden and antibiotic resistance patterns can assist with development of strategies, updating of guidelines and subsequent improvement in initial empirical therapy. OBJECTIVES: To determine whether the empirical antibiotic choice for treatment of septic episodes at a district-level hospital was appropriate according to national guidelines, and to describe the epidemiological features of the septic episode population being studied and depict their antibiotic susceptibility profile. METHODS: This was a retrospective, descriptive study of adult inpatients with bloodstream infections at Karl Bremer Hospital, Cape Town, South Africa. Laboratory and clinical data were obtained and analysed for the period 1 July 2017 - 30 June 2018. Septic episodes were subdivided into community-acquired bloodstream infection (CABSI) and hospital-acquired bloodstream infection (HABSI) study populations, and empirical antibiotics for both groups were assessed and compared with the adult Standard Treatment Guidelines and Essential Medicines List for South Africa, Hospital Level Care, 2015 edition (STG and EML). RESULTS: Our study sample consisted of 184 septic episodes, isolated from 176 patients. Nearly half of the septic episodes (49.5%) were hospital acquired. Overall guideline adherence in the CABSI population was 88%, compared with 58% in the HABSI population. The reasons for guideline non-adherence in the CABSI population were lack of source-appropriate empirical antibiotics (n=7) and septic episodes where empirical antibiotics were indicated but not prescribed (n=4), while in the HABSI group the main reason was that the patients were treated by community-acquired standards (n=30; 33.0%). The in-hospital mortality rate for a septic episode in this study was 38%. Considering the typical first-line antibiotics used, 77.3% of CABSIs were found to be susceptible to co-amoxiclav (n=75) and 59.8% to ceftriaxone (n=58). With the exclusion of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii isolates as confounders, HABSIs had a susceptibility of 86% to the piperacillin/tazobactam plus amikacin combination, 81% to ertapenem, 90% to imipenem and 93% to meropenem. CONCLUSIONS: This study demonstrates poor guideline adherence in HABSIs, emphasising the importance of distinguishing between CABSIs and HABSIs. The empirical antibiotics advised by the STG and EML were found to be appropriate in the majority of septic episodes. Future revision and improvement of prescribing practices can assist in rationalising empirical antibiotic decisions.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Cross Infection/drug therapy , Sepsis/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Community-Acquired Infections/microbiology , Cross Infection/microbiology , Female , Guideline Adherence , Hospitals, District , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Practice Guidelines as Topic , Retrospective Studies , Sepsis/microbiology , South Africa , Young Adult
5.
PLoS One ; 16(11): e0257272, 2021.
Article in English | MEDLINE | ID: mdl-34780494

ABSTRACT

INTRODUCTION: Hospital admitted patients are at increased risk of nosocomial infections (NIs) with multi-drug resistant (MDR) pathogens which are prevalent in the hospital environment. Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) are common causes of NIs worldwide. The objective of this study is to determine antimicrobial resistance profiles and associated factors of Acinetobacter spp and P. aeruginosa NIs among hospitalized patients. METHODS: A cross-sectional study was conducted at Dessie comprehensive specialized hospital, North-East Ethiopia, from February 1 to April 30, 2020. A total of 254 patients who were suspected of the bloodstream, urinary tract, or surgical site nosocomial infections were enrolled consecutively. Socio-demographic and other variables of interest were collected using a structured questionnaire. Specimens were collected and processed following standard microbiological procedures. Antimicrobial susceptibility was determined using the Kirby-Bauer disk diffusion method following Clinical and Laboratory Standards Institute guidelines. Data were analyzed with SPSS version 23 and p-value < 0.05 was considered statistically significant. RESULTS: Overall, 13% of patients had nosocomial Acinetobacter spp and/or P. aeruginosa infections. The culture positivity rate was 16(6.3%) for Acinetobacter spp and 18(7.1%) for P. aeruginosa. Patients admitted in the surgical ward (Adjusted odds ratio (AOR):10.66;95% confidence interval (CI):1.22-93.23), pediatric ward (AOR:14.37;95%CI:1.4-148.5), intensive care unit (AOR:41.93;95%CI:4.7-374.7) and orthopedics (AOR:52.21;95%CI:7.5-365) were significantly at risk to develop NIs compared to patients admitted in the medical ward. Patients who took more than two antimicrobial types at admission were 94% (AOR:0.06; 95% CI:0.004-0.84) times more protected from NIs compared to those who did not take any antimicrobial. About 81% of Acinetobacter spp and 83% of P. aeruginosa isolates were MDR. Amikacin and meropenem showed promising activity against Acinetobacter spp and P. aeruginosa isolates. CONCLUSION: The high prevalence of MDR Acinetobacter spp and P. aeruginosa nosocomial isolates enforce treating of patients with NIs based on antimicrobial susceptibility testing results.


Subject(s)
Acinetobacter Infections/drug therapy , Acinetobacter baumannii/drug effects , Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Drug Resistance, Multiple, Bacterial/drug effects , Hospitals, Special , Meropenem/therapeutic use , Patient Admission , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Acinetobacter Infections/epidemiology , Acinetobacter Infections/microbiology , Acinetobacter baumannii/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Amikacin/pharmacology , Anti-Bacterial Agents/pharmacology , Child , Child, Preschool , Cross Infection/microbiology , Cross-Sectional Studies , Ethiopia/epidemiology , Female , Humans , Infant , Infant, Newborn , Male , Meropenem/pharmacology , Microbial Sensitivity Tests , Middle Aged , Pseudomonas Infections/epidemiology , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Risk Factors , Treatment Outcome , Young Adult
6.
Medicine (Baltimore) ; 100(21): e26158, 2021 May 28.
Article in English | MEDLINE | ID: mdl-34032774

ABSTRACT

ABSTRACT: The aim of this study was to analyze the distribution of pathogenic bacteria in hospitalized patients in elderly care centers under the mode of integration of medical care and elderly care service, and explore the influencing factors to reduce the health care-associated infection rate of hospitalized patients.A total of 2597 inpatients admitted to elderly care centers from April 2018 to December 2019 were included in the study. The etiology characteristics of health care-associated infections (HCAI) was statistically analyzed, univariate analysis, and multivariate logistic regression analysis method were used to analyze the influencing factors of HCAI.A total of 98 of 2597 inpatients in the elderly care centers had HCAI, and the infection rate was 3.77%. The infection sites were mainly in the lower respiratory tract and urinary tract, accounting for 53.92% and 18.63%, respectively. A total of 53 pathogenic bacteria were isolated, 43 of which (81.13%) were Gram-negative, mainly Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae, which respectively accounted for 24.53, 16.98, and 13.21%. 9 (16.98%) strains were Gram-positive, mainly Staphylococcus aureus and Enterococcus faecium, respectively accounting for 7.55 and 5.66%. Only 1 patient (1.89%) had a fungal infection. Multivariate logistic regression analysis indicated that total hospitalization days, antibiotic agents used, days of central line catheter, use of urinary catheter and diabetes were independent risk factors of nosocomial infection in elderly care centers (P < .05).Many factors can lead to nosocomial infections in elderly care centers. Medical staff should take effective intervention measures according to the influencing factors to reduce the risk of infection in elderly care facilities.


Subject(s)
Cross Infection/epidemiology , Cross Infection/microbiology , Delivery of Health Care, Integrated , Homes for the Aged/organization & administration , Hospitals, Public/organization & administration , Aged , Anti-Bacterial Agents/therapeutic use , China/epidemiology , Cross Infection/drug therapy , Cross-Sectional Studies , Female , Humans , Length of Stay , Male , Risk Factors
7.
Ann Clin Microbiol Antimicrob ; 20(1): 34, 2021 May 13.
Article in English | MEDLINE | ID: mdl-33985505

ABSTRACT

BACKGROUND: The incidence of Candida bloodstream infections (BSIs), has increased over time. In this study, we aimed to describe the current epidemiology of Candida BSI in a large tertiary care hospital in Shanghai and to determine the risk factors of 28-day mortality and the impact of antifungal therapy on clinical outcomes. METHODS: All consecutive adult inpatients with Candida BSI at Ruijin Hospital between January 1, 2008, and December 31, 2018, were enrolled. Underlying diseases, clinical severity, species distribution, antifungal therapy, and their impact on the outcomes were analyzed. RESULTS: Among the 370 inpatients with 393 consecutive episodes of Candida BSI, the incidence of nosocomial Candida BSI was 0.39 episodes/1000 hospitalized patients. Of the 393 cases, 299 (76.1%) were treated with antifungal therapy (247 and 52 were treated with early appropriate and targeted antifungal therapy, respectively). The overall 28-day mortality rate was 28.5%, which was significantly lower in those who received early appropriate (25.5%) or targeted (23.1%) antifungal therapy than in those who did not (39.4%; P = 0.012 and P = 0.046, respectively). In multivariate Cox regression analysis, age, chronic renal failure, mechanical ventilation, and severe neutropenia were found to be independent risk factors of the 28-day mortality rate. Patients who received antifungal therapy had a lower mortality risk than did those who did not. CONCLUSIONS: The incidence of Candida BSI has increased steadily in the past 11 years at our tertiary care hospital in Shanghai. Antifungal therapy influenced short-term survival, but no significant difference in mortality was observed between patients who received early appropriate and targeted antifungal therapy.


Subject(s)
Antifungal Agents/therapeutic use , Candida/drug effects , Candida/isolation & purification , Cross Infection/epidemiology , Cross Infection/microbiology , Sepsis/epidemiology , Sepsis/microbiology , Adult , Aged , Candidiasis/epidemiology , Candidiasis/microbiology , Candidiasis/mortality , China/epidemiology , Cross Infection/drug therapy , Cross Infection/mortality , Female , Humans , Incidence , Inpatients , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Risk Factors , Sepsis/drug therapy , Sepsis/mortality , Tertiary Care Centers , Treatment Outcome
8.
Sci Rep ; 11(1): 10556, 2021 05 18.
Article in English | MEDLINE | ID: mdl-34006956

ABSTRACT

The spread of multidrug resistant organisms (MDRO) is a global healthcare challenge. Nosocomial outbreaks caused by MDRO are an important contributor to this threat. Computer-based applications facilitating outbreak detection can be essential to address this issue. To allow application reusability across institutions, the various heterogeneous microbiology data representations needs to be transformed into standardised, unambiguous data models. In this work, we present a multi-centric standardisation approach by using openEHR as modelling standard. Data models have been consented in a multicentre and international approach. Participating sites integrated microbiology reports from primary source systems into an openEHR-based data platform. For evaluation, we implemented a prototypical application, compared the transformed data with original reports and conducted automated data quality checks. We were able to develop standardised and interoperable microbiology data models. The publicly available data models can be used across institutions to transform real-life microbiology reports into standardised representations. The implementation of a proof-of-principle and quality control application demonstrated that the new formats as well as the integration processes are feasible. Holistic transformation of microbiological data into standardised openEHR based formats is feasible in a real-life multicentre setting and lays the foundation for developing cross-institutional, automated outbreak detection systems.


Subject(s)
Cross Infection/microbiology , Drug Resistance, Microbial , Electronic Health Records/standards , Computer Simulation , Cross Infection/epidemiology , Disease Outbreaks , Humans , Interinstitutional Relations , Proof of Concept Study , Reference Standards
9.
PLoS One ; 16(5): e0250525, 2021.
Article in English | MEDLINE | ID: mdl-33945553

ABSTRACT

Klebsiella pneumoniae is a major pathogen implicated in nosocomial infections. Extended-spectrum ß-lactamase (ESBL)-producing K. pneumoniae isolates are a public health concern. We aim to characterize the type of ß-lactamases and the associated resistance mechanisms in ESBL-producing K. pneumoniae isolates obtained from blood cultures in a Portuguese hospital, as well as to determine the circulating clones. Twenty-two cefotaxime/ceftazidime-resistant (CTX/CAZR) K. pneumoniae isolates were included in the study. Identification was performed by MALDI-TOF MS and the antimicrobial susceptibility testing by disk-diffusion. The screening test for ESBL-production was performed and ESBL-producer isolates were further characterized. The presence of different beta-lactamase genes (blaCTX-M, blaSHV, blaTEM, blaKPC, blaNDM, blaVIM, blaOXA-48, blaCMY-2, blaDHA-1, blaFOX, blaMOX, and blaACC) was analyzed by PCR/sequencing in ESBL-producer isolates, as well as the presence of other resistance genes (aac(6')-Ib-cr, tetA/B, dfrA, qnrA/B/S, sul1/2/3) or integron-related genes (int1/2/3). Multilocus-sequence-typing (MLST) was performed for selected isolates. ESBL activity was detected in 12 of the 22 CTX/CAZR K. pneumoniae isolates and 11 of them carried the blaCTX-M-15 gene (together with blaTEM), and the remaining isolate carried the blaSHV-106 gene. All the blaCTX-M-15 harboring isolates also contained a blaSHV gene (blaSHV-1, blaSHV-11 or blaSHV-27 variants). Both blaSHV-27 and blaSHV-106 genes correspond to ESBL-variants. Two of the CTX-M-15 producing isolates carried a carbapenemase gene (blaKPC2/3 and blaOXA-48) and showed imipenem resistance. The majority of the ESBL-producing isolates carried the int1 gene, as well as sulphonamide-resistance genes (sul2 and/or sul3); the tetA gene was detected in all eight tetracycline-resistant isolates. Three different genetic lineages were found in selected isolates: ST348 (one CTX-M-15/TEM/SHV-27/KPC-2/3-producer isolate), ST11 (two CTX-M-15/TEM/SHV-1- and CTX-M-15-TEM-SHV-11-OXA-48-producer isolates) and ST15 (one SHV-106/TEM-producer isolate). ESBL enzymes of CTX-M-15 or SHV-type are detected among blood K. pneumoniae isolates, in some cases in association with carbapenemases of KPC or OXA-48 type.


Subject(s)
Cefotaxime/therapeutic use , Ceftazidime/therapeutic use , Drug Resistance, Multiple, Bacterial , Klebsiella Infections/pathology , Klebsiella pneumoniae/genetics , Sepsis/pathology , beta-Lactamases/genetics , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Cross Infection/genetics , Cross Infection/microbiology , Cross Infection/pathology , Humans , Klebsiella Infections/drug therapy , Klebsiella Infections/genetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Microbial Sensitivity Tests , Multilocus Sequence Typing/methods , Sepsis/drug therapy , Sepsis/genetics , Sepsis/microbiology , Sequence Analysis, DNA/methods
11.
Molecules ; 26(3)2021 Jan 26.
Article in English | MEDLINE | ID: mdl-33530597

ABSTRACT

Caralluma europaea (Guss.) N.E.Br.: (C. europaea) is a wild medicinal plant belonging to the family Apocynaceae. It is commonly used in traditional medicines for treating several diseases. The present work aims to evaluate the anti-inflammatory, antibacterial, and antifungal potentials of C. europaea fractions including hydro ethanol (ET CE), n-butanol (But CE), and polyphenol (Poly CE). The chemical composition of hydroethanol, n-butanol, and polyphenol-rich fractions from C. europaea were determined using GC-MS after silylation. The anti-inflammatory effect of hydroethanol, n-butanol, and polyphenol-rich fractions was studied by carrageenan-induced paw edema. Antibacterial and antifungal activities of hydroethanol, n-butanol, and polyphenol-rich fractions against Gram-positive bacteria, Gram-negative bacteria, and yeasts were assessed using the disc diffusion and micro-dilution assays. The findings of the chemical characterization affirmed the presence of interesting bioactive compounds in C. europaea fractions. The polyphenol-rich fraction was the best inhibitor of edema by75.68% after 6 h of treatment. The hydroethanol fraction was the most active against both bacteria and yeasts. This study contributes to society as it provides potential bioactive compounds in C. europaea extract, which may help in fighting nosocomial antibiotic-resistant microbes.


Subject(s)
Anti-Infective Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Apocynaceae/chemistry , Cross Infection/microbiology , Inflammation/drug therapy , Phytochemicals/administration & dosage , 1-Butanol/administration & dosage , 1-Butanol/isolation & purification , 1-Butanol/pharmacology , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/isolation & purification , Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Antifungal Agents/administration & dosage , Antifungal Agents/isolation & purification , Antifungal Agents/pharmacology , Candida albicans/drug effects , Carrageenan/adverse effects , Cross Infection/drug therapy , Drug Resistance, Bacterial/drug effects , Drug Resistance, Fungal/drug effects , Female , Gas Chromatography-Mass Spectrometry , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Humans , Inflammation/chemically induced , Male , Microbial Sensitivity Tests , Phytochemicals/isolation & purification , Phytochemicals/pharmacology , Polyphenols/administration & dosage , Polyphenols/isolation & purification , Polyphenols/pharmacology , Rats , Saccharomyces cerevisiae/drug effects
12.
BMC Infect Dis ; 21(1): 16, 2021 Jan 06.
Article in English | MEDLINE | ID: mdl-33407206

ABSTRACT

BACKGROUND: Epidemiological data of cephalosporin-resistant Enterobacterales in Sub-Saharan Africa is still restricted, and in particular in Mozambique. The aim of this study was to detect and characterize extended-spectrum ß-lactamase (ESBL) - and plasmid-mediated AmpC (pAmpC)-producing clinical strains of Escherichia coli at Maputo Central Hospital (MCH), a 1000-bed reference hospital in Maputo, Mozambique. METHODS: A total of 230 clinical isolates of E. coli from urine (n = 199) and blood cultures (n = 31) were collected at MCH during August-November 2015. Antimicrobial susceptibility testing was performed by the disc diffusion method and interpreted according to EUCAST guidelines. Isolates with reduced susceptibility to 3rd generation cephalosporins were examined further; phenotypically for an ESBL-/AmpC-phenotype by combined disc methods and genetically for ESBL- and pAmpC-encoding genes by PCR and partial amplicon sequencing as well as genetic relatedness by ERIC-PCR. RESULTS: A total of 75 isolates with reduced susceptibility to cefotaxime and/or ceftazidime (n = 75) from urine (n = 58/199; 29%) and blood (n = 17/31; 55%) were detected. All 75 isolates were phenotypically ESBL-positive and 25/75 (33%) of those also expressed an AmpC-phenotype. ESBL-PCR and amplicon sequencing revealed a majority of blaCTX-M (n = 58/75; 77%) dominated by blaCTX-M-15. All AmpC-phenotype positive isolates (n = 25/75; 33%) scored positive for one or more pAmpC-genes dominated by blaMOX/FOX. Multidrug resistance (resistance ≥ three antibiotic classes) was observed in all the 75 ESBL-positive isolates dominated by resistance to trimethoprim-sulfamethoxazole, ciprofloxacin and gentamicin. ERIC-PCR revealed genetic diversity among strains with minor clusters indicating intra-hospital spread. CONCLUSION: We have observed a high prevalence of MDR pAmpC- and/or ESBL-producing clinical E. coli isolates with FOX/MOX and CTX-Ms as the major ß-lactamase types, respectively. ERIC-PCR analyses revealed genetic diversity and some clusters indicating within-hospital spread. The overall findings strongly support the urgent need for accurate and rapid diagnostic services to guide antibiotic treatment and improved infection control measures.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/genetics , Cefotaxime/therapeutic use , Ceftazidime/therapeutic use , Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli Infections/drug therapy , Escherichia coli/enzymology , Escherichia coli/isolation & purification , Plasmids/metabolism , beta-Lactamases/genetics , Cross Infection/diagnosis , Cross Infection/microbiology , Escherichia coli Infections/blood , Escherichia coli Infections/epidemiology , Escherichia coli Infections/urine , Humans , Microbial Sensitivity Tests , Mozambique/epidemiology , Phenotype , Prevalence
13.
Microbiologyopen ; 9(11): e1121, 2020 11.
Article in English | MEDLINE | ID: mdl-32985133

ABSTRACT

Candida tropicalis is a common human pathogenic yeast, and its molecular typing is important for studying the population structure and epidemiology of this opportunistic yeast, such as epidemic genotype, population dynamics, nosocomial infection, and drug resistance surveillance. In this study, the antifungal susceptibility test and multilocus sequence typing (MLST) analysis were carried out on C. tropicalis from central China. Among 64 urogenital isolates, 45 diploid sequence types (DST) were found, of which 20 DSTs (44.4%) were new to the central database. The goeBURST analysis showed that CC1 (clonal complex) was the only azole-resistant (100%, 10/10) cluster in Wuhan, which was composed of DST546, DST225, DST376, and DST506, and most of the strains (90%, 9/10) were isolated from the urinary tract. Potential nosocomial infections were mainly caused by CC1 strains. The azole resistance rate of urinary isolates (50.0%, 21/42) was higher than that of vaginal isolates (27.3%, 6/22). The genotype diversity and novelty of vaginal isolates were higher than those of urinary isolates. C. tropicalis population in Wuhan was genetically diverse and divergent from that seen in other countries. In this study, there were significant differences in genotype and azole susceptibility between urine and vaginal strains. The azole-resistant cluster (CC1) found in urine is of great significance for the clinical treatment and prevention of nosocomial infection. The newly discovered DSTs will contribute to further study the similarity, genetic relationship, and molecular epidemiology of C. tropicalis worldwide.


Subject(s)
Azoles/therapeutic use , Candida tropicalis/isolation & purification , Candidiasis/epidemiology , Drug Resistance, Fungal/genetics , Reproductive Tract Infections/epidemiology , Urinary Tract Infections/epidemiology , Antifungal Agents/therapeutic use , Candida tropicalis/drug effects , Candida tropicalis/genetics , Candidiasis/drug therapy , Candidiasis/microbiology , China/epidemiology , Cross Infection/microbiology , Female , Humans , Male , Microbial Sensitivity Tests , Molecular Epidemiology , Multilocus Sequence Typing , Mycological Typing Techniques , Reproductive Tract Infections/drug therapy , Reproductive Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology
14.
Mycoses ; 63(12): 1373-1381, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32885534

ABSTRACT

OBJECTIVES: Candidemia is among the most frequent nosocomial bloodstream infections. Landmark case-control studies on amphotericin B and fluconazole estimated attributable mortality rates of 38% and 49%, respectively. After introduction of echinocandins, these may have decreased. METHODS: In a case-control design, 100 consecutive, hospitalised patients with candidemia were enrolled at the University Hospital of Cologne, Germany between 2014 and 2017. Controls were patients without candidemia matched for age, sex, year and duration of hospitalisation, main admission diagnosis and Patient Clinical Complexity Level (PCCL). Main data captured were risk factors for candidemia, attributable mortality rates and diagnostic and therapeutic adherence according to the EQUAL Candida score. RESULTS: Overall mortality rates for cases and controls were 43% and 17% (P < .001), respectively; day 30 mortality rates were 38% and 11% (P = .03), accounting for an attributable mortality of 26% and 27%. Guideline adherence was higher in surviving vs non-surviving patients: while survivors reached a median of 17 (IQR: 16-19) points, non-surviving cases reached a median 16 (IQR: 14-18) points out of 22 maximum achievable points (P = .028). Risk factors for candidemia were more frequent in cases compared to control patients, especially chronic pulmonary disease (25% vs 16%; P = n.s.), chronic liver disease (21% vs 6%; P = .002), stay on intensive care unit (70% vs 64%; P = n.s.), respiratory failure (56% vs 50%; P = n.s.) and central venous catheter (97% vs 35%; P < .001). CONCLUSIONS: Attributable mortality of nosocomial candidemia is still substantial but has decreased compared to previous studies with similar design.


Subject(s)
Antifungal Agents/therapeutic use , Candidemia/drug therapy , Candidemia/mortality , Echinocandins/therapeutic use , Hospital Mortality , Aged , Amphotericin B/therapeutic use , Candida/drug effects , Case-Control Studies , Cross Infection/drug therapy , Cross Infection/microbiology , Female , Germany , Hospitalization , Hospitals, University/statistics & numerical data , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Risk Factors
15.
Biomed Pharmacother ; 130: 110606, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32795924

ABSTRACT

The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Clove Oil/pharmacology , Colistin/pharmacology , Cross Infection/microbiology , Klebsiella pneumoniae/drug effects , Oils, Volatile/pharmacology , Syzygium/chemistry , Thymus Plant/chemistry , Drug Resistance, Multiple, Bacterial/drug effects , Drug Synergism , Humans , Microbial Sensitivity Tests
16.
Acta Biochim Pol ; 67(3): 387-392, 2020 Jul 31.
Article in English | MEDLINE | ID: mdl-32735431

ABSTRACT

The emergence of resistance against commonly used antibiotics has become a serious global concern. The rapid development of antibiotic resistance exhibited by Enterobacteriaceae has caused an increasing concern regarding untreatable bacterial infections. Here, we isolated four pathogens from a geriatric female patient who was hospitalized for a month with ventilator-associated pneumonia (VAP) and fever. The organisms isolated from the tracheal aspirates and urine included Klebsiella pneumoniae, pandrug-resistant Providencia rettgeri, and Acinetobacter baumannii. Resistome analysis indicated that the bacterial isolates from the polymicrobial infection were multiple-drug resitnat and pandrug resistant clones. Molecular characterization revealed presence of blaTEM-1 in K. pneumonaie, P. rettgeri and A. baumannii. The blaTEM-1 and blaNDM-1 genes were present in P. rettgeri and A. baumannii, whereas the blaTEM-1, blaNDM-1 and blaOXA-23 traits were present in A. baumannii isolates. The patient has died due to the unavailability of effective antimicrobial treatment for this drug-resistant polymicrobial infection.


Subject(s)
Acinetobacter Infections/drug therapy , Acinetobacter baumannii/genetics , Anti-Bacterial Agents/therapeutic use , Coinfection/drug therapy , Cross Infection/drug therapy , Drug Resistance, Multiple, Bacterial/genetics , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/genetics , Pneumonia, Ventilator-Associated/drug therapy , Providencia/genetics , Rural Population , Acinetobacter Infections/microbiology , Coinfection/microbiology , Cross Infection/microbiology , Fatal Outcome , Female , Genes, Bacterial , Genotype , Humans , India , Klebsiella Infections/microbiology , Microbial Sensitivity Tests , Middle Aged , Pneumonia, Ventilator-Associated/microbiology
17.
BMC Infect Dis ; 20(1): 597, 2020 Aug 12.
Article in English | MEDLINE | ID: mdl-32787942

ABSTRACT

BACKGROUND: Multidrug resistant (MDR) and extensively drug resistant (XDR) Acinetobacter baumannii presents challenges for clinical treatment and causes high mortality in children. We aimed to assess the risk factors and overall mortality for MDR/XDR Acinetobacter baumannii infected pediatric patients. METHODS: This retrospective study included 102 pediatric patients who developed MDR/XDR Acinetobacter baumannii infection in the pediatric intensive care unit (PICU) of Shanghai Children's Hospital in China from December 2014 to May 2018. Acinetobacter baumannii clinical isolates were recovered from different specimens including blood, sputum, bronchoalveolar lavage fluid, cerebrospinal fluid, ascites, hydrothorax, and urine. Antibiotic susceptibility test was determined according to the Clinical and Laboratory Standards Institute interpretive criteria. Clinical and biological data were obtained from the patients' medical records. RESULTS: 102 patients with Acinetobacter baumannii infection were enrolled. The median age was 36 (9.6, 98.8) months, and there were 63 male in the case group. The overall mortality rate was 29.4%, while the Acinetobacter baumannii-associated mortality rate was 16.7% (17/102, 12 bloodstream infections, 4 meningitis and 1 intra-abdominal infection). Bloodstream infections occurred in 28 patients (27.5%), and 10 patients (9.8%) among them had central line-associated bloodstream infections (6 central venous catheters, 2 PICCs, 1 venous infusion port and 1 arterial catheter). Cerebrospinal fluid (CSF) cultures were positive in 4(3.9%) patients. 14(13.7%) patients got positive cultures in ascites and hydrothorax. Lower respiratory isolates (56/102) accounted for 54.9% of all patients. Non-survival patients appeared to have a lower NK cell activity (6.2% ± 3.61% vs. 9.15% ± 6.21%, P = 0.029), higher CD4+ T cell ratio (39.67% ± 12.18% vs. 32.66% ± 11.44%, P = 0.039),and a higher serum level of interlukin-8 (IL-8, 15.25 (1.62, 47.22)pg/mL vs. 0.1 (0.1, 22.99)pg/mL, P = 0.01) when Acinetobacter baumannii infection developed. Multivariate logistic analysis indicated that high serum level of Cr (RR, 0.934, 95%CI, 0.890-0.981; P = 0.007) and high BUN/ALB level (RR, 107.893, 95%CI, 1.425-870.574; p = 0.005) were associated with high risk of mortality in MDR/XDR Acinetobacter baumannii infected patients. CONCLUSION: MDR/XDR Acinetobacter baumannii infection is a serious concern in pediatric patients with high mortality. Bloodstream and central nervous system infection accounted for high risk of death. Acute kidney injury is associated with high risk of mortality.


Subject(s)
Acinetobacter Infections/drug therapy , Acinetobacter Infections/mortality , Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Cross Infection/mortality , Drug Resistance, Multiple, Bacterial/drug effects , Intensive Care Units, Pediatric , Acinetobacter Infections/microbiology , Acinetobacter baumannii/isolation & purification , Acute Kidney Injury/mortality , Bacteremia/mortality , Central Nervous System Infections/mortality , Child , Child, Preschool , China , Cross Infection/microbiology , Female , Hospitals , Humans , Infant , Male , Microbial Sensitivity Tests , Retrospective Studies , Risk Factors , Treatment Outcome
18.
BMC Infect Dis ; 20(1): 411, 2020 Jun 12.
Article in English | MEDLINE | ID: mdl-32532220

ABSTRACT

BACKGROUND: The prevalence of healthcare-acquired infections (HAI) and rising levels of antimicrobial resistance places significant economic and public health burdens on modern healthcare systems. A group of highly drug resistant pathogens known as the ESKAPE pathogens, along with C. difficile, are the leading causes of HAIs. Interactions between patients, healthcare workers, and environmental conditions impact disease transmission. Studying pathogen transfer under varying contact scenarios in a controlled manner is critical for understanding transmission and disinfectant strategies. In lieu of human subject research, this method has the potential to contribute to modeling the routes of pathogen transmission in healthcare settings. METHODS: To overcome these challenges, we have developed a method that utilizes a synthetic skin surrogate to model both direct (skin-to-skin) and indirect (skin-to fomite-to skin) pathogen transfer between infected patients and healthy healthcare workers. This surrogate material includes a background microbiome community simulating typical human skin flora to more accurately mimic the effects of natural flora during transmission events. RESULTS: We demonstrate the ability to modulate individual bacterial concentrations within this microbial community to mimic bacterial concentrations previously reported on the hands of human subjects. We also explore the effect of various decontamination approaches on pathogen transfer between human subjects, such as the use of handwashing or surface disinfectants. Using this method, we identify a potential outlier, S. aureus, that may persist and retain viability in specific transfer conditions better than the overall microbial community during decontamination events. CONCLUSIONS: Our work describes the development of an in vitro method that uses a synthetic skin surrogate with a defined background microbiota to simulate skin-to-skin and skin-to fomite-to skin contact scenarios. These results illustrate the value of simulating a holistic microbial community for transfer studies by elucidating differences in different pathogen transmission rates and resistance to common decontamination practices. We believe this method will contribute to improvements in pathogen transmission modeling in healthcare settings and increase our ability to assess the risk associated with HAIs, although additional research is required to establish the degree of correlation of pathogen transmission by skin or synthetic alternatives.


Subject(s)
Cross Infection/microbiology , Cross Infection/transmission , Models, Biological , Clostridioides difficile , Cross Infection/prevention & control , Decontamination/methods , Drug Resistance, Microbial , Fomites/microbiology , Humans , Microbial Viability , Microbiota , Skin/microbiology , Species Specificity
19.
Sci Rep ; 10(1): 6497, 2020 04 16.
Article in English | MEDLINE | ID: mdl-32300130

ABSTRACT

Drug resistance in Clostridioides difficile becomes a public health concern worldwide, especially as the hypervirulent strains show decreased susceptibility to the first-line antibiotics for C. difficile treatment. Therefore, the simultaneous discovery and development of new compounds to fight this pathogen are urgently needed. In order to determinate new drugs active against C. difficile, we identified ticagrelor, utilized for the prevention of thrombotic events, as exhibiting potent growth-inhibitory activity against C. difficile. Whole-cell growth inhibition assays were performed and compared to vancomycin and metronidazole, followed by determining time-kill kinetics against C. difficile. Activities against biofilm formation and spore germination were also evaluated. Leakage analyses and electron microscopy were applied to confirm the disruption of membrane structure. Finally, ticagrelor's ability to synergize with vancomycin and metronidazole was determined using checkerboard assays. Our data showed that ticagrelor exerted activity with a MIC range of 20-40 µg/mL against C. difficile. This compound also exhibited an inhibitory effect on biofilm formation and spore germination. Additionally, ticagrelor did not interact with vancomycin nor metronidazole. Our findings revealed for the first time that ticagrelor could be further developed as a new antimicrobial agent for fighting against C. difficile.


Subject(s)
Clostridioides difficile/drug effects , Clostridium Infections/drug therapy , Cross Infection/drug therapy , Drug Repositioning , Ticagrelor/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Biofilms/drug effects , Biofilms/growth & development , Cell Membrane/drug effects , Cell Membrane/ultrastructure , Clostridioides difficile/cytology , Clostridium Infections/microbiology , Cross Infection/microbiology , Drug Evaluation, Preclinical , Drug Resistance, Bacterial/drug effects , Drug Synergism , Humans , Metronidazole/pharmacology , Metronidazole/therapeutic use , Microbial Sensitivity Tests , Microscopy, Electron , Spores, Bacterial/drug effects , Spores, Bacterial/growth & development , Ticagrelor/therapeutic use , Vancomycin/pharmacology
20.
R I Med J (2013) ; 103(2): 24-27, 2020 Mar 02.
Article in English | MEDLINE | ID: mdl-32122096

ABSTRACT

C. difficile is a complication of antibiotic therapy. Certain antibiotics are associated with a higher rate of developing C. difficile. The charts of 54 patients with nosocomial C. difficile were reviewed and very few had received a high-risk antibiotic. Seven (13%) of 54 patients had not received any antibiotics in the hospital prior to the positive stool test for C. difficile. Moreover, 6 of the 7 had no documentation of receiving an antibiotic in the 56 days prior to admission suggesting that they might be colonized with C. difficile.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/drug effects , Clostridium Infections/drug therapy , Cross Infection/drug therapy , Inappropriate Prescribing/adverse effects , Inpatients , Adult , Aged , Aged, 80 and over , Clostridioides difficile/isolation & purification , Clostridium Infections/diagnosis , Clostridium Infections/epidemiology , Cross Infection/microbiology , Female , Hospitals , Humans , Incidence , Inpatients/statistics & numerical data , Length of Stay , Male , Microbial Sensitivity Tests , Middle Aged , Rhode Island/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL